Company presentation - Mondobiotech

Introduction to our
business, August 2010
SIX Swiss
Exchange
Symbol R
ARE

Disclaimer
The shares of Mondobiotech Holding AG have been traded since August 26th,
2009 on the SIX Swiss Exchange with the symbol RARE.
This document does not constitute or form
part, or all, of any offer or invitation to sell or
issue, neither in the United States of America
nor elsewhere, or any solicitation of any offer to
purchase or subscribe for, any securities, nor shall
part, or all, of this document or its distribution
form the basis of, or be relied on in connection
with, any contract or investment decision in
relation to any securities.
This document includes forward-looking
statements that involve substantial risks and
uncertainties. These forward-looking statements
are based on the Company’s current expectations
and projections about future events.
All statements, other than statements of historical
facts, included in this document regarding the
Company’s future operations, future financial
position, future revenues, projected costs,
plans and objectives of management
are forward-looking statements.
The words “anticipates”, “believes”, “estimates”,
“expects”, “intends”, “may”, “plans”, “projects”,
“will”, “would” and similar expressions are
intended to identify forward-looking statements,
although not all forward-looking statements
contain these identifying words. The Company
may not achieve the plans, intentions or
expectations disclosed in its forward-looking
statements and there can be no assurance that
results of the Company’s activities and its results
of operations will not differ materially from its
expectations.
This document is from Mondobiotech
Holding AG. The information contained
in it is intended solely for the use of the
individual or entity to which they are addressed.
Any unauthorized dissemination or copying
of this document, is strictly prohibited
and may be illegal.
2/33

The context
30’000 is the total number of known diseases at present.
7’000 diseases are neglected or rare
A Rare Disease is:
In USA a disease affecting less than 200’000 people.
In Europe disease affecting less than 5 in 10’000 people
6% to 8% of the world population
is affected by a rare disease
In USA 30 million affected.
In Europe 35 million affected.
In the World 622 million affected.
Generally there is no therapy for these patients
3/33

Founders’ vision
“for us, Mondobiotech is a long term
project for changing the world of medicine
in rare and neglected diseases.”
(Fabio, Dorian, Patrick, Vera)
4/33

Value drivers of our business
• In the classical pharmaceutical and biotech
field there is no correlation between
resources invested in R&D and the resulting
output obtained, at least not measurable
in the numbers of new medicaments.
Therefore, the development process is
probably characterised by other value drivers.
• We believe that in-depth information
exchange, interaction, versatility and flexibility
are such value drivers. Therefore, we
operate with a continuously expanding
community (scientists, physicians, patients,
patient advocacy organisations etc.)
who share their experience, know-how,
expertise and skills with us and who, like us,
are dedicated to the search of treatments
for rare and neglected diseases
(the “Mondobiotech community”).
+ + +
connect partecipate collaborate discuss
5/33

Mission & business model
Finding Therapies for Rare Diseasesof known dis
• Mondobiotech is a Swiss search biotech
company focused on finding treatments for
rare and neglected diseases through
our unique “Search & Match” engine.
• The company partners with relevant
communities or parties who are interested in
reaching solutions for specific rare diseases.
• We obtain effective and safe Medicinal
Product Candidates (MPC’s) through redirecting
existing and known substances into new
therapeutic indications.
• We analyze peptides and other biological
immunomodulating substances that are
naturally occurring in the human body
in order to identify promising candidates
for the development of medicinal
products for use in the treatment of rare
and neglected diseases.
• The Search & Match engine combined
with the know-how of our worldwide orphan
scientific community has so far discovered
more then 300 MPC’s for further exploration
in as many as possible of the 7’000 rare
and neglected diseases.
• We license or sell our MPC’s to third parties
(such as pharmaceutical or biotechnology
companies) and/or to collaborate with
third parties to obtain market authorizations
and to commercialize such candidates.
6/33

Key competitive strength
Dry search rather than classical
laboratory research (Search & Match):
• By using IT tools and a proven methodology
we search the vast amount of globally available
data on biological and medical activities
on known peptides and other biological
immunomodulating substances as opposed to
engaging in the traditional approach of drug
discovery.
Focus on bioactive substances
of human origin (peptides):
• We believe that peptides of human origin
offer better efficacy and safety profiles
compared to other classes of molecular
entities.
Focus on rare and neglected diseases:
• We believe that rare and neglected diseases
offer strong competitive advantage.
Working and networking in a global
community:
• We believe that the mondoBIOTECH
community is the only way to generate and
conceive hundreds of MPC’s.
Dual protection of the business:
• Innovative intellectual property concepts
and market protection through Orphan
Medicinal Product Designations (OMPD) giving
regulatory exclusivity for as much as seven
years in the US, and 10 years in Europe and
some other parts of the world.
Outsourcing supervised by management:
• The outsourcing of all non-core activities
enables us to focus on our business model.
7/33

Mondobiotech Community
Mondobiotech collaborates with two types of communities:
Scientists:
• From the beginning, Mondobiotech chose and
developed an open and collaborative scientific model
that allows the exchange of knowledge and data.
• Our frequent workshops and online collaborations
enable a high level of participation allowing a natural
and structural growth of the scientific community.
Patients Associations:
• To support the communities of patients associations
Mondobiotech has developed an innovative collaborative project:
the Stop Rare Foundation, www.stoprare.org.
• Stoprare.org is the online place for patients associations
to find, bring, support and exchange information
on rare and neglected diseases, projects, research, etc.
• Stop Rare Foundation’s goal is to improve the lives
of patients with rare diseases and their families.
8/33

Model validation
For our vision, business model and potential impact on world health,
the World Economic Forum selected us as Technology Pioneer 2008.
“Why the company is a pioneer:
Developments in technology have brought
better medicines within the grasp of many
patients. However, drug development remains
expensive, so most large drug companies play
it safe and concentrate on widespread diseases.
Companies such as mondobiotech play an
increasingly important role in making sure that
sufferers of lesser-known diseases eventually
find relief from their conditions”.
(Technology Pioneer Report 2008, p.14)
“To be selected as a Technology Pioneer,
a company must be involved in the
development of life-changing technology
innovation and have potential for long–term
impact on business and society. In addition,
it must demonstrate visionary leadership,
show the signs of being a long-standing
market leader - and its technology must
be proven”. (Rodolfo Lara,
WEF’s Technology Pioneer program)
Technology Pioneers were Google, Mozilla, the Wikimedia Foundation and Twitter.
9/33

The orphan market
• Worldwide, the orphan drug market reached
$84.9 billion in 2009. The market is expected
to grow at a compound annual growth
rate (CAGR) of nearly 6% to reach $112.1 billion
by 2014. The US accounted for 51% of the
market in 2009 and is expected to grow at
a CAGR of 8.9% to reach $65.9 billion by 2014.
• The total worldwide market for orphan
drugs, including sales for non-orphan
applications, exceeded $28 billion in 2003. The
market reached $58.7 billion in 2006, growing
by 8% from $54.5 billion in 2005
in orphan applications only.
• Biological drugs accounted for a major share
(64.3%) of the orphan drug market with sales
of $54.6 billion in 2009, up from $51.4 billion
(Source: www.bccresearch.com/report/PHM038C.html, published:
May 2010, analyst: Syamala Ariyanchira, and reports of 2004 and 2007)
in 2008. The size of the biological orphan drug
market is projected to grow
at a 6.9% CAGR to reach $76.2 billion by 2014.
• In 2009 there were a total of more then
350 orphan drugs approved in USA
and 62 in Europe.
• 57 drugs exceeded yearly sales of $200
million and 27 of those exceeded sales
of $1 billion.
10/33

Search & Match
312 medicaments
for Rare and Neglected diseases
Product candidates basic characteristics:
• Peptides of human origin with known
biological activity.
• Synthetically manufactured.
• Well researched by the global scientific
community.
• Proven safety profile.
• Mode of action through ligation to specific
receptors.
• Same peptide or with minor modification
present in many other species, which indicates
that is an ancient molecule important for the
basic metabolism of life.
• Therapeutic platform potential.
11/33

Examples of platforms’ rationales
Interferon - γ (DK 1001)
Known biological activity:
• Antifibrotic
• Antiproliferative
• Antibiotic
Safety:
• Approved for pediatric
and adult use via subcutaneous
injection in Chronic
Granulomatous disease
(CGD) and severe malignant
osteopetrosis.
Rare indications and route
of administration:
• IPF via inhalation.
• Two other indications
via injection and inhalation
to be disclosed after
IP protection.
Aviptadil (DK 1000)
Known biological activity:
• Antinflammatory
• Immunoregulatory
• Antiproliferative
• Antibiotic
• Antiapoptotic
Safety:
• Approved in combination
with phentolamine
in erectile dysfunction.
• Used in various clinical
trials in lung diseases over
more than 2 decades
and hundreds of patients.
Homology with other species:
• Identical in the following species:
human, cow, rat, pig, dog, goat,
sheep, mouse, monkey.
Rare indications and route
of administration:
• PAH via inhalation.
• Sarcoidosis via inhalation.
• ARDS via injection.
• IPF via inhalation.
DasKloster 0210 (DK 0210)
Known biological activity:
• Immunoregulatory
• Anti-pyretic
• Antiproliferative
• Antiallergic
• Antifibrotic
• Antinflammatory
Safety:
• Approved in combination
with met-enkephaline
for multiple sclerosis.
Homology with other species:
• Identical in Human, mice, rat, pig.
Rare indications and route
of administration:
• Chronic Beryllium Disease
via injection.
• Glomerulonephrytis
via injection.
• Chronic Fatigue Syndrome
via injection.
12/33

IP protection & orphan market exclusivity
Intellectual Property protection and market exclusivity are essential for succeeding in developing new therapeutic
options in rare diseases. Our products platforms are protected in a dual way, through Orphan Drug Status
Designations and a novel patent concept on products and/or indications.
Orphan Drug Regulations
in Europe and USA
• In USA rare diseases are regulated by the Jan. 4th,
1983 Orphan Drug Act (ODA).
• In Europe rare diseases are regulated by the year
2000 EU Regulation 141/2000.
• Major advantages of the Orphan Drug Regulations are:
• Grants for research.
• Free protocol advice assistance.
• Free or consistent costs reductions
for new applications, marketing
authorizations and post-authorization
activities.
• Fast-track procedures and approvals.
• Seven years (USA) and ten years
(EU) market exclusivity after market authorization.
Mondobiotech
Orphan Drug Status Designations (ODS)
2003 EMEA:
ODS for Aviptadil in PAH and CTEPH received 23/12/2003
(EU/3/03/173).
2005 FDA:
ODS for Aviptadil in PAH received 22/02/2005.
2005 EMEA:
ODS for Interferon gamma in IPF received 30/05/2005
(EU/3/05/281).
2005 FDA:
ODS for Aviptadil in ARDS received 01/06/2005.
2006 EMEA:
ODS for Aviptadil in Acute Lung Injury (ALI)
received 28/08/2006 (EU/3/06/395).
Mondobiotech Patents
2005: Interferon gamma patent (EP 0 795 332 B1) for: “Medical use of Gamma Interferon in Interstitial Lung Diseases” received 01/06/2005.
2007: Started the patent application program to cover more than 300 product platforms for rare diseases.
13/33

Licensing package
Products ready to enter negotiation for licensing
are accompanied by full product documentation
that interested parties can request.
Documentation includes:
Medicinal Product Candidate
Development Activities
Diseases
Financial Information
IP & Legal
Offered Services
Dossier, API information, Published information.
In vitro activities, Pre-clinical activities, Clinical activities.
Disease dossier, Centers of excellence, Patients associations & other key entities,
Published data, Development plan.
Key competitor, Other market information, Projected sales.
Protection documentation, PCT application, ISR (if available), National applications
(if available): USA, Europe, Australia, Canada, Japan, Singapore, United Arab Emirates,
Korea, Russia. Orphan drug designations/Orphan drug application and granting
(EU/US), EU Regulations, US Regulations, Standard licensing contract and conditions,
Standard service contract.
API, Protocol assistance, Orphan drug & Regulatory assistance, Networking with
Mondobiotech Community (Scientific, Medical, Centers of excellence, Laboratory,
Research organizations and other experts), Scientific & Medical Workshops for developing
and prompting the project, Co-marketing, other development services upon request.
14/33

Licensed pipeline
Search & Match
Patent Applied
Pre-clinical
Development
with the Community
ready for licensing in negotiation licensed
Phase I
Phase II
Phase III
Marketing
Autorization Applied
Marketing Approved
DasKloster 1001-01
Idiopathic Pulmonary Fibrosis (IPF) InterMune Inc.
DasKloster 1000-01
Pulmonary Arterial Hypertension (PAH)
DasKloster 1000–02
Sarcoidosis
DasKloster 1000–03
Idiopathic Pulmonary Fibrosis (IPF)
DasKloster 1000–04
Acute Respiratory Distress Syndrome (ARDS/ALI)
DasKloster 0138–01
Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis
Phase IV
Biogen Idec Inc. & Lung Rx, LLC
Lung Rx, LLC
Lung Rx, LLC
Lung Rx, LLC
Lung Rx, LLC
15/33

Licensed products
Aviptadil platform to Lung Rx (Nasdaq: UTHR), incl. Biogen Idec (Nasdaq: BIIB)
DasKloster 1000-01
Indication:
Milestones:
Royalties:
Peak sales:
Status:
Next milestone*:
DasKloster 1000-03
Indication:
Milestones:
Royalties:
Peak sales:
Status:
Next milestone*:
DasKloster 1000-02
Indication:
Milestones:
Royalties:
Peak sales:
Status:
Next milestone*:
DasKloster 1000-04
Indication:
Milestones:
Royalties:
Peak sales:
Status:
Next milestone*:
Pulmonary Arterial Hypertension (PAH)
US$ 10m end of phase III; US$ 20m marketing authorization
approx. 10% on net sales on the whole platform
estimated US$ 1.5 billion (comparables: Actelion (ATLN))
preparation of phase III
end of phase III expected in 2013
Idiopathic Pulmonary Fibrosis (IPF)
US$ 10m end of phase III; US$ 10m marketing authorization
approx. 10% on net sales on the whole platform
estimated US$ 1.5 billion Status:
preparation of phase IIb
end of phase III expected in 2013
Sarcoidosis
US$ 10m end of phase III; US$ 10m marketing authorization
approx. 10% on net sales on the whole platform
estimated US$ 200 million
preparation of phase IIb
end of phase III expected in 2013
Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
US$ 10m end of phase III; US$ 10m marketing authorization
approx. 10% on net sales on the whole platform
estimated US$ 200m
preparation of phase II
end of phase III expected in 2013
* based on, and subject to, licensing partners development plans. 16/33

Licensed products
Secretin to Lung Rx (Nasdaq: UTHR)
DasKloster 0138-01
Indication:
Milestones:
Royalties:
Peak sales:
Status:
Next milestone*:
4 further MPC for lung diseases to be chosen by Lung Rx (Nasdaq: UTHR)
Interferon-γ to Intermune (Nasdaq: ITMN)
DasKloster 1001-01
Indication:
Peak sales:
Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis (MRSA in CF)
US$ 100’000 signing-up, US$ 1m end of phase II; US$ 10m marketing authorization
10% on net sales
US$ 200m
clinical development started
end of phase II expected in 2012
Lung Rx, a wholly-owned subsidiary of United Therapeutics (Nasdaq: UTHR), has the right to choose between additional 4 MPC
within our pipeline at its discretion. Same conditions as above. Peak sales estimated between US$ 100 - 200 million.
Idiopathic Pulmonary Fibrosis (IPF)
US$ 100 - 400 million (source: Global Data - IPF market report 2010)
The project is on-hold at Intermune and will not more generate revenue flows. Based on our
know-how in IPF, we intend to re-define the formulation and the clinical development of INF-γ
and working for having this drug approved for IPF.
* based on, and subject to, licensing partners development plans. 17/33

Licensed pipeline
DasKloster 0182–01
Sarcoidosis
DasKloster 0210–01
Chronic Beryllium Disease
DasKloster 0274–01
Pseudomonas Aeruginosa in Cystic Fibrosis
DasKloster 0249–01
Drug-Resistant Tuberculosis
DasKloster 0247–01
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
DasKloster 0080-01
Lymphangioleiomyomatosis (LAM)
DasKloster 0039–01
Asbestosis
DasKloster 0112-01 + DasKloster 0228–01
Scleroderma
28 Medicinal Product Candidates
Target not disclosed
260 Medicinal Product Candidates
Target not disclosed
Search & Match
Patent Applied
Pre-clinical
Development
with the Community
ready for licensing in negotiation licensed
Phase I
Phase II
Phase III
Marketing
Autorization Applied
Marketing Approved
Phase IV
In collaboration with Pharmarare SA
18/33

Products for licensing
MPC at advanced development stage
We intend to enter into licensing-out agreements. We are also evaluating new approaches for financing further development, and with
respect to one of such MPC, a development contribution agreement for CHF 1.5 million is in place with Pharmarare SA (privately held company).
Once commercialized, we will share milestones and royalties on such MPC. We estimate a standard licensing-out agreement structure
as it was the case with Lung Rx but with favorable royalty rates and peak sales for these MPC between US$ 100 - 200 million.
DasKloster 0182-01
DasKloster 0210-01
DasKloster 0274-01
DasKloster 0249-01
DasKloster 0247-01
DasKloster 0080-01
DasKloster 0039-01
DasKloster 0112-01 + DasKloster 0228-01
MPC at early development stage
We work with the mondobiotech community to complete the dossiers and have them ready to further development and/or out-licensed.
We estimate a standard licensing-out agreement structure pursuant to the above and peak sales for these MPC between US$ 100 - 150 million.
• 28 MPC’s (targets undisclosed)
Patent filed pipeline
IP filed for patent granting (start nationalization phases first half 2010) covering the MPC’s in different disease areas and ready for being further
developed and/or licensed. We estimate a standard licensing-out agreement structure at least as it was the case with United Therapeutics and
peak sales on these MPC between US$ 50 - 150 million.
• 260 MPC’s (targets undisclosed)
Sarcoidosis
Chronic Beryllium Disease (CBD)
Pseudomonas Aeruginosa in Cystic Fibrosis
XDR & MDR Tuberculosis
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Lymphangioleiomyomatosis (LAM)
Asbestosis
Scleroderma
19/33

Business validation
Science
IP
Business
Strategic Alliances
Financial
Founders
More than 300 potentially efficacious treatments discovered.
1 product in phase III and 4 products in phase II clinical trials,
6 products ready to enter in clinical trials phases, 32 products to start
clinical development, 260 products to start development.
6 Orphan Medicinal Products Designations in USA and Europe, 1 patent
granted for IFN-γ (EP 0 795 332 B1) and the products in the pipeline
protected by patent applications.
10 indications licensed to two partners, InterMune and Lung Rx, a United
Therapeutics subsidiary (incl. Biogen Idec), and capacity to license more.
23andMe for genetic research for patients in rare diseases;
Bachem for peptides manufacturing; Nebu-Tec for inhalation;
SRI for preclinical testing and biological screening.
Traded at the SIX Swiss Exchange with symbol RARE,
top investors from family firms continue their commitment
to the company, BSI bank of Generali Insurance Group
as house bank and WR Hambrecht bank as financial advisor.
Majority shareholders still involved as from the beginning with the same
long term investment vision.
20/33

WR Hambrecht+Co.
• Founded in 1998 by William R. Hambrecht,
WR Hambrecht + Co is a financial services firm committed
to using technology and auction processes to provide
open and fair access to financial markets for all its clients.
The firm’s impartial auctions, which allow the market to
determine pricing and allocation, are dramatically changing
the financial services landscape. www.wrhambrecht.com
• William R. Hambrecht in 1968 co-founded Hambrecht &
Quist, an investment banking firm specialized in emerging
high-growth technology companies that was sold in 1999
for US$ 1.35B to Chase Manhattan Bank.
• WR Hambrecht + Co. and Mondobiotech signed
a collaboration agreement in April 2010 for the exclusive
placement of Mondobiotech securities and other financial
and strategic services.
• WR Hambrecht + Co. has auctioned in the last decade
some of the most important IPOs including Google, NetSuite
and Morningstar plus other important placements.
21/33

Stock snapshot
Reported capital Commercial register
Listed share capital (in units) 1'327'805 Share capital (in units) 54'229'365
Listed share capital CHF 132'781 Share capital CHF 661'797
Conditional capital (in units) 3'269'413
Conditional capital CHF 326'941
Authorised capital (in units) 3'190'279
Authorised capital CHF 319'028
Shares detail
Valor symbol RARE Trading 26.08.2009 -
Valor number 10'191'073 Security type Registered share
ISIN CH0101910732
Trading currency CHF Security segment Swiss Shares
Exchange SIX Swiss Exchange Primary listed yes
Product line Mid & Small Caps Swiss Shares
Issued by mondoBIOTECH holding AG Regulatory standard Main Standard
Number in issue 1'327'805 Clearing via SegaInterSettle AG
Nominal value 0.10 Settlement currency CHF
Dividend entitlement 1x per year
R ARE
SIX Swiss
Exchange
Symbol
Index member SPI SXI Bio+Medtech
SPI Extra SXI Life Sciences
SPI ex SLI Swiss All Share Index
Sarasin Swiss IPO Index
Stock value on July 27th, 2010 at 5pm: CHF 73.00
Market Cap on July 27th, 2010 at 5pm: CHF 483.11 million
Stock quote online www.six-swiss-exchange.com/shares/security_info_en.html?id=CH0101910732CHF4
22/33

Share capital structure
A corporate structure to ensure stability and a long time horizon:
• The original investors and co-founders
own the unlisted share majority with privileged
voting rights in order to underscore their
commitment.
• The community can also hold a financial
stake in the company by purchasing SIX
Swiss Exchange listed shares.
• This dual share structure generates stability
in the long term and ensures the company’s
leadership team maintains the ability to
continue the innovative approach that has
characterized the company from the outset
without it suffering from an unfriendly
take-over or any other form of control oriented
speculation.
• Google, The New York Times,
The Washington Post, The Wall Street Journal,
Roche and Berkshire Hathaway (a Warren
Buffett’s subsidiary) are all examples of
companies having a similar capital structure.
23/33

Financial strategy
Small, flexible and specialized
organization with high value added
profile and clear cost structure for:
• discovering and conceiving MPC’s
• interacting and networking with
the Mondobiotech community
• outsourcing all non-core activities
Aggressive licensing strategy
breaking the tradition:
• moderate signing-up and milestones
at early development stages
• significant milestones and royalties at,
and after, marketing authorization
Goals:
• demonstrate effectiveness and efficacy
of the business model
• finance organic growth of the structure
through multiple fund raisings
• enlarge shareholders’ basis through
the public listing of the company
Financials:
• Cash and Cash equivalents on Dec. 31st 2009:
4,6mio.
• Raised on Jan. 25th 2010:
net CHF 8,5mio.
• Expenses estimation for 2010:
CHF 12,6mio.
24/33

Financial data - segment reporting
(in 1’000 CHF)
‘Project’ segment (core):
• moderate cost effect of our discovering and conceiving approach and the community networking clearly stated.
• we are able to generate revenues.
‘Services’ segment (not core - deriving from collaborations with licensing-out partners):
• our partners are ready to pay for high value added services.
* Financial data are in thousand CHF. Adjustments may not exactly correspond to audited financial data.
Projects Services Corporate Total
31.12.2009:
Revenues from external customers 610 13.130 - 13.740
Inter-segment revenues 95 - 685 780
Segmental costs (13.398) (11.496) (1.735) (26.628)
Segmental operating results (12.693) 1.635 (1.050) (12.108)
Included in segmental operating resut are>
- depreciacion, amortization and other write-offs (5.336) (108) - (5.444)
31.12.2008:
Revenues from external customers 316 14.229 - 14.545
Inter-segment revenues 262 - 632 894
Segmental costs (11.622) (12.349) (637) (24.608)
Segmental operating results (11.044) 1.880 (5) (9.169)
Included in segmental operating resut are>
- depreciacion, amortization and other write-offs (3.402) (206) (36) (3.644)
25/33

Financial data - global view
(in 1’000 CHF)
We generated operating revenues of CHF 45.5 million in the last years (2006 - 2009)
from licensing out (11.5m) and development services (34m), against operating expenses of CHF 74.7 million.
We raised net proceeds of CHF 28 million in the same period. On February we closed a further reserved
fund raising for net CHF 8.5 million. To fund the further development of our pipeline, we plan additional share
capital increases. We intend to issue new shares to investors and to the Mondobiotech community.
* Financial data are in thousand CHF. Adjustments may not exactly correspond to audited financial data.
2009 2008 2007 2006
Revenues 13.740 14.545 14.827 2.480
Research & development (20.146) (20.173) (11.291) (4.824)
Sales & marketing (3.632) (2.351) (3.762) (2.047)
Management & administration (2.071) (1.192) (1.510) (1.754)
Operating result (12.108) (9.170) (1.735) (6.145)
Total non-current and other current assets 60.586 62.576 68.121 61.458
Cash and cash equivalents 4.632 14.085 11.009 15.306
Total assets 65.218 76.662 79.130 76.764
Total shareholder's equity 56.733 68.937 64.496 66.134
Liabilities 8.486 7.725 14.634 10.630
Total equities and liabilities 65.218 76.662 79.130 76.764
26/33

Financial Calendar
Next Corporate Appointments:
• August 31st 2010
• March 31st 2011
• April/May 2011
Half Year Financial Results 2010
Annual Report 2010
Ordinary General Assembly, DasKlosterStans
For additional information on please contact Mondobiotech Investor & External Relations:
investor@mondobiotech.com - T. +41 840 200 010.
27/33

Management
Patrick
Pozzorini
Chief Financial
Officer, founder.
Patrick holds a degree
in business economics
from the University
of Zurich. From 1995
to 2000, he worked
for Pricewaterhouse
Coopers AG and
from 1992 to 1995
for Fidinam Group.
He was born in 1967.
Vera
Cavalli
Chief Pharmaceutical
Officer, founder.
Vera graduated
in pharmacy at the
University of Basel.
She gained five years
of pharmacy business
experience working
in various pharmacies.
From 1999 to 2000
she worked in the sales
department for the
Swiss market of Searle
SA (Monsanto group).
She was born in 1968.
Fabio
Cavalli
Executive Chairman
& Chief Business Architect,
founder.
Fabio has founded
several successful
start-ups in IT,
consumer services
and sports goods
fields, gaining
thereby considerable
marketing and
sales experience.
Fabio is Swiss
Entrepreneur of
the year 2006.
He was born in 1955.
Ruggero
Gramatica
Chief Executive Officer.
Ruggero has an extensive
experience in startups
and companies’
turnaround particularly
in the services industry
having successfully
contributed to the
growth of Fastweb,
Covad Communications,
PacificBell, Omnitel-
Vodafone, Bulldog
and OnTelecoms .
He brings strategic
leadership as
well as technological
and operational
expertise to bear.
He was born in 1965.
Maria Teresa
D’Antonangelo
Chief Operating Officer.
Maria Teresa graduated
in Law at the University
of Parma. She specialized
in the field of Intellectual
and Industrial Property
Litigations with Prof.
Mario Franzosi in Milan.
She has been admitted
to the Doctorate in
Intellectual Property Law
at the University of Parma.
She was born in 1973.
Dorian
Bevec
Chief Scientific
Officer, founder.
Dorian holds a Ph.D.
from the Ludwig-
Maximilians-University
of Munich and a habilitation
(Venia Docendi) from
the University of Vienna.
He worked as Head
of Molecular Biology
and project team leader
at the Sandoz Research
Institute in Vienna for ten
years and at Axxima AG
in Martinsried for two years.
He was born in 1957.
28/33

Board
Robert Edward
Patterson
Managing Director
Peninsula Venture
Fabio Cavalli
Executive Chairman,
Chief Business
Architect, founder
Prof.
Michael Alan Keller
Stanford University Librarian
Graf Francis
von Seilern-Aspang
CEO Industrie u. Finanzkontor
Prof. Dr. Med.
Thomas Cerny
Head of Oncology,
University of St. Gallen
Prinz Michael von
und zu Liechtenstein
Vice – Chairman
Ruggero
Gramatica
CEO Mondobiotech
Prof.
Geoffrey West
Distinguished Professor and former
President of the Santa Fe Institute
Vera Cavalli
Chief Pharmaceutical
Officer, founder
Prof. Dr.
Robert Huber
Nobel Prize Laureate
Prof.
Roland M. du Bois
Professor of Respiratory Medicine,
Imperial College, London
29/33

Awards
2008
Mondobiotech
recepient
of The Swiss
Innovation
Award by
the Central
Swiss Chamber
of Commerce.
2007
Mondobiotech
selected as
Technology
Pioneer
by the World
Economic
Forum.
2007
Mondobiotech
selected by
an independent
jury as the
Best Innovator.
2006
Chief Business
Architect
Fabio Cavalli
receives
Start-up Swiss
Entrepreneur
of the Year.
2005
Winner
of the Swiss Life
Sciences Prize.
30/33

About us
• We started the Company in 2001 on two
fundamental ideas: use known, existing substances
with safe profiles; interact and network with the
communities.
• The first licensing-out agreement was signed
at the end 2001/beginning 2002 with NASDAQ-listed
Intermune, Inc.
• From 2001 to 2006 we developed the methodology
to continuously generate a large number of MPC’s,
the Search & Match Engine.
• In 2006 we closed our second licensing-out
agreement with NASDAQ-listed Biogen Idec, Inc.
• In 2007, we entered into a third licensing-out
agreement with NASDAQ-listed United Therapeutics,
Inc. for five MPC projects at ‘dry search’ stage only.
This agreement was important for us insofar as
it demonstrated the scientific foundation of our
business model.
• In 2009 we began a partnership with 23andMe, Inc.
to advance research in collecting data by genotyping
patients affected by rare diseases.
• As of August 2009 the shares of the Company are
listed on the SIX Swiss Exchange with the symbol
RARE.
• In September 2009 we enforced our agreement
with SIX-listed Bachem Holding AG with respect to
peptides in the development of MPC’s.
• Beginning 2010 we expanded our agreement
with Biogen Idec Inc. to United Therapeutics, Inc.,
therefore ensuring the development of Aviptadil to a
whole platform.
• In April 2010 we signed a collaboration agreement
with WR Hambrecht + Co. for the exclusive
placement of Mondobiotech securities and other
financial and strategic services.
• To date, we have more then 300 MPCs covered by
intellectual property for further development and/or
licensing.
31/33

Meet us
Selected management will present the company at the following conferences:
• Sept. 13-15, 2010
• Sept. 15-17, 2010
• Sept. 29-30, 2010
• Oct. 10-12, 2010
Rodman & Renshaw 12th Annual Healthcare Conference New York Palace Hotel,
New York USA
www.rodm.com/conferences
BioPharm America 2010 Marriot Boston Copley Place, Boston USA
www.ebdgroup.com/bpa/index.php
10th Annual Biotech in Europe Investor Forum
Radisson Blu Hotel, Zurich Airport Switzerland
www.sachsforum.com/zurich10/index.html
Mondobiotech will present on Sept. 29th in the afternoon session
18th Annual BioPartnering Europe QEII Conference Center, London
UK www.techvision.com/bpe
Mondobiotech will present on Oct. 12th at 9.30am in the Abbey Room West
To organize 1-to-1 meetings with the management at these events or in other venues please contact
Mondobiotech Investor & External Relations: investor@mondobiotech.com - T. +41 840 200 010.
32/33

Mondobiotech Holding AG
DasKloster
Mürgstrasse 18
CH – 6370 Stans
Switzerland
www.mondobiotech.com
IR Contact
Paolo Bassanini
T +41 840 200 010
F +41 840 200 011
investor@mondobiotech.com